Abstract

Faecalibacterium prausnitzii is a major commensal bacterium in the human gut. It produces short-chain fatty acids that promote intestinal health. However, the bacterium is extremely oxygen-sensitive, making it difficult to develop as a probiotic. To facilitate practical application of F. prausnitzii, we investigated factors that affect its growth and mammalian gut colonization. We evaluated cross-feeding interactions between F. prausnitzii and seven Bifidobacterium strains, and the anti-inflammatory properties of bacterial metabolites produced in co-culture, in vitro and in vivo. Co-culture of F. prausnitzii and Bifidobacterium catenulatum, with fructooligosaccharides as an energy source, resulted in the greatest viable cell-count and butyrate production increases. Further, the co-culture supernatant reduced the amount of proinflammatory cytokines produced by HT-29 cells and RAW 264.7 macrophages, an effect that was similar to that of butyrate. Furthermore, feeding mice both Faecalibacterium and Bifidobacterium enhanced F. prausnitzii gut colonization. Finally, feeding the co-culture supernatant decreased interleukin 8 levels in the colon and increased butyrate levels in the cecum in the dextran sodium sulfate-induced colitis mouse model. These observations indicate that the Faecalibacterium-Bifidobacterium co-culture exerts an anti-inflammatory effect by promoting F. prausnitzii survival and short-chain fatty acid production, with possible implications for the treatment of inflammatory bowel disease.

Highlights

  • Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by inflammation and tissue damage in the distal ileum and colon

  • We showed that acetate and degraded dietary fiber produced by different Bifidobacterium species promote the growth of F. prausnitzii, with cross-feeding resulting in increased butyrate production

  • F. prausnitzii is a good biomarker for a healthy gut, and its abundance is reduced in Crohn’s disease [14]

Read more

Summary

Introduction

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by inflammation and tissue damage in the distal ileum and colon. The incidence of IBD in the wealthy western countries has been increasing since the mid-twentieth century. Gut dysbiosis is considered a novel pivotal factor associated with IBD pathogenesis and is characterized by a decreased diversity of the gut microbiota. Anti-inflammatory drugs used for treating IBD partially relieve the disease symptoms; the use of the drugs results in side effects such as headache and diarrhea, which lead to a poor quality of life [6]. This calls for novel treatment strategies, such as the use of probiotics

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call